Charles River and MEDIPOST deepen cell therapy testing push across APAC and North America
Cell therapy scale-up is not just a science problem. Charles River and MEDIPOST are targeting the GMP testing bottleneck.
Medipost raises $140m to fund U.S. Phase III trial of stem cell therapy for knee osteoarthritis
Medipost secures $140M to fund a pivotal U.S. Phase III trial in osteoarthritis. See how this could reshape the future of scalable stem cell therapies.